Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, February 10, 2018

Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review

Maybe you'll want this. There is also this article from 2013 but in mice, so if your doctor did no followup you have an incompetent doctor.
7. Wei N., et al. Delayed intranasal delivery ofhypoxic-preconditioned bone marrow mesenchymal stem  cells enhanced cell homing andtherapeutic benefits after ischemic stroke in mice.  Cell Transplantation, 2013. 22(6) p. 977-991.

And this from Dec. 2016:

How to Improve Your Memory, Mood and Energy with Intranasal Insulin

The latest here:

Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review


  • Konstantinos Ioannis Avgerinos
  • Grigorios Kalaitzidis
  • Antonia Malli
  • Dimitrios Kalaitzoglou
  • Pavlos Gr. Myserlis
  • Vasileios-Arsenios Lioutas
  • Konstantinos Ioannis Avgerinos
    • 1
    • 2
    • 5
  • Grigorios Kalaitzidis
    • 2
    • 5
  • Antonia Malli
    • 3
    • 5
  • Dimitrios Kalaitzoglou
    • 3
    • 5
  • Pavlos Gr. Myserlis
    • 4
    • 5
  • Vasileios-Arsenios Lioutas
    • 6
  1. 1.251 Hellenic Airforce General HospitalAthensGreece
  2. 2.Department of Medicine, Faculty of Health SciencesAristotle University of ThessalonikiThessalonikiGreece
  3. 3.Faculty of MedicineNational and Kapodistrian University of AthensAthensGreece
  4. 4.401 General Army HospitalAthensGreece
  5. 5.Society of Junior DoctorsAthensGreece
  6. 6.Department of Neurology, Division of Cerebrovascular Diseases, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA
Review
First Online: 01 February 2018



Abstract

Background and aims

Due to common pathophysiological findings of Alzheimer’s disease (AD) with diabetes mellitus (DM), insulin has been suggested as a possible treatment of AD or mild cognitive impairment (MCI). A safe alternative of IV insulin is intranasal (IN) insulin. The aim of this systematic review is to investigate the effects of IN insulin on cognitive function of patients with either AD or MCI.

Methods

A literature search of the electronic databases Medline, Scopus and CENTRAL was performed to identify RCTs investigating the effect of IN insulin administration on cognitive tasks, in patients with AD or MCI.

Results

Seven studies (293 patients) met our inclusion criteria. Most studies showed that verbal memory and especially story recall was improved after IN insulin administration. Sometimes the effect was restricted for apoe4 (−) patients. Intranasal insulin did not affect other cognitive functions. However, there were some positive results in functional status and daily activity. Data suggested that different insulin types and doses may have different effects on different apoe4 groups. In addition, the effects of treatment on Αβ levels differed from study to study. Finally, IN insulin resulted in minor adverse effects.

Conclusions

Intranasal insulin improved story recall performance of apoe4 (−) patients with AD or MCI. Other cognitive functions were not affected, but there were some positive results in functional status and daily activity. Since IN insulin is a safe intervention, future studies should be conducted with larger doses and after proper selection of patients and insulin types.
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)